Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Change in Accured Expenses: 2010-2024

Historic Change in Accured Expenses for China Pharma Holdings (CPHI) over the last 15 years, with Dec 2024 value amounting to $432,051.

  • China Pharma Holdings' Change in Accured Expenses fell 21.64% to -$68,702 in Q3 2025 from the same period last year, while for Sep 2025 it was $762,943, marking a year-over-year increase of 520.43%. This contributed to the annual value of $432,051 for FY2024, which is 67.61% up from last year.
  • China Pharma Holdings' Change in Accured Expenses amounted to $432,051 in FY2024, which was up 67.61% from $257,778 recorded in FY2023.
  • In the past 5 years, China Pharma Holdings' Change in Accured Expenses registered a high of $692,190 during FY2022, and its lowest value of -$111,160 during FY2020.
  • For the 3-year period, China Pharma Holdings' Change in Accured Expenses averaged around $460,673, with its median value being $432,051 (2024).
  • Per our database at Business Quant, China Pharma Holdings' Change in Accured Expenses skyrocketed by 473.61% in 2021 and then slumped by 62.76% in 2023.
  • Yearly analysis of 5 years shows China Pharma Holdings' Change in Accured Expenses stood at -$111,160 in 2020, then spiked by 473.61% to $415,309 in 2021, then skyrocketed by 66.67% to $692,190 in 2022, then tumbled by 62.76% to $257,778 in 2023, then spiked by 67.61% to $432,051 in 2024.